Shares of MEDNAX Inc (NYSE:MD) have been assigned a consensus recommendation of “Hold” from the sixteen research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $53.82.
A number of equities analysts recently issued reports on MD shares. KeyCorp upgraded shares of MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a research report on Sunday, September 17th. Jefferies Group reissued a “hold” rating and set a $46.00 target price on shares of MEDNAX in a report on Tuesday, October 3rd. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. BMO Capital Markets began coverage on shares of MEDNAX in a report on Monday, October 16th. They set a “market perform” rating and a $46.00 target price on the stock. Finally, Robert W. Baird boosted their target price on shares of MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd.
In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares in the company, valued at $1,883,116.85. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.
MEDNAX (MD) traded down $0.11 during mid-day trading on Monday, reaching $54.50. 1,116,700 shares of the company were exchanged, compared to its average volume of 956,375. The firm has a market cap of $5,104.21, a PE ratio of 19.26, a price-to-earnings-growth ratio of 1.64 and a beta of 0.39. MEDNAX has a twelve month low of $40.56 and a twelve month high of $72.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37.
MEDNAX (NYSE:MD) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.87. The business had revenue of $868.95 million during the quarter, compared to analysts’ expectations of $864.78 million. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.09 EPS. analysts predict that MEDNAX will post 3.1 EPS for the current fiscal year.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.